PNC-27
OtherPreclinicalAlso known as: PNC-27 peptide, p53-HDM2 inhibitor peptide, anti-cancer peptide
PNC-27 is a p53-derived peptide that selectively induces membranolysis in cancer cells. It contains the p53 transactivation domain (amino acids 17–26) linked to a membrane-penetrating transmembrane domain (HDM2 binding domain).
Overview
At A Glance
PNC-27 contains a p53 transactivation domain sequence (residues 17-26) and a membrane-penetrating HDM2-binding sequence. Cancer cells aberrantly express HDM2 protein on their plasma membrane surface (while normal cells retain it intracellularly). PNC-27 binds surface-expressed HD…
Overview
PNC-27 is a p53-derived peptide that selectively induces membranolysis in cancer cells. It contains the p53 transactivation domain (amino acids 17–26) linked to a membrane-penetrating transmembrane domain (HDM2 binding domain). Uniquely, PNC-27 kills cancer cells by binding to HDM2 protein on the cancer cell membrane surface — where HDM2 (the p53 negative regulator) is aberrantly expressed — creating pores in the cancer cell plasma membrane. Normal cells, which do not express surface HDM2, are spared. This selectivity distinguishes PNC-27 from most cytotoxic compounds. Published research comes primarily from Sarafraz-Yazdi et al. and has demonstrated selective pancreatic cancer, leukemia, and breast cancer cell kill in vitro. PNC-27 remains preclinical with no clinical trials completed.
Chemical Information
IUPAC Name
Not yet available
CAS Number
Not yet available
Molecular Formula
Not yet available
Molecular Mass
Not yet available
Chemical data is being compiled for this compound.
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Interaction and contraindication data is being compiled for PNC-27. Check back soon.
General Safety Note
Always consult a qualified healthcare professional before combining research compounds. Interactions may exist that are not yet documented.
$119.00
$11.9000
1
1
vial
| Vendor | Product | Form | Qty | Price | $/mg | Coupon | |
|---|---|---|---|---|---|---|---|
 |
PNC-27 10mg | vial | 1 vial● Out of Stock | $119.00BEST | $11.900 | — | Sign in for stock alert |
Tracking since Apr 22, 2026 · 1 data point
Vendors Selling PNC-27
How we score these vendors
Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.
Related Compounds
View AllAminotadalafil
OtherPreclinicalAminotadalafil is an unapproved research analog of tadalafil, the PDE5 inhibitor marketed under the brand name Cialis for erectile dysfunction and under Adcirca for pulmonary arterial hypertension.
B7-33
OtherPreclinicalB7-33 is a single-chain, 26-amino-acid peptide engineered as a functionally selective agonist of the relaxin family peptide receptor 1 (RXFP1), designed to recapitulate the therapeutic activity of human H2 relaxin — the endogenous peptide hormone that is naturally elevated during pregnancy and has broad cardioprotective, vasodilatory, and anti-fibrotic effects.
KSPTN
OtherPreclinicalKSPTN is a novel research peptide available from select peptide research vendors.
Melanotan I
OtherFDA ApprovedMelanotan I (afamelanotide) is a linear synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) with the substitution of norleucine at position 4 and D-phenylalanine at position 7.
Prostamax
OtherPreclinicalProstamax is a short synthetic peptide developed in Russia by Vladimir Khavinson and collaborators at the St.
RU-58841
OtherPreclinicalRU-58841 (also known as PSK-3841 or HMR-3841, and commonly written simply as RU in hair-loss forums) is a non-steroidal androgen receptor antagonist originally developed by Roussel Uclaf (later absorbed into Sanofi) in the late 1980s and early 1990s.
View Full Dosage Guide →
Protocols, calculator & safety for PNC-27
Research Score
0 PubMed studies
Quality Indicators
Data Completeness
63%Quick Facts
Half-Life
Unknown (no published PK data)
Administration
Subcutaneous, Intravenous, Intraperitoneal
Trial Phase
Preclinical
Safety Profile
Common Side Effects
- • No human safety data exists
- • In vitro toxicity against cancer cells only
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is PNC-27 used for in research?
PNC-27 is a p53-derived peptide that selectively induces membranolysis in cancer cells. It contains the p53 transactivation domain (amino acids 17–26) linked to a membrane-penetrating transmembrane domain (HDM2 binding domain). Uniquely, PNC-27 kills cancer cells by binding to HDM2 protein on the cancer cell membrane surface — where HDM2 (the p53 negative regulator) is aberrantly expressed — creating pores in the cancer cell plasma membrane. Normal cells, which do not express surface HDM2, are spared. This selectivity distinguishes PNC-27 from most cytotoxic compounds. Published research comes primarily from Sarafraz-Yazdi et al. and has demonstrated selective pancreatic cancer, leukemia, and breast cancer cell kill in vitro. PNC-27 remains preclinical with no clinical trials completed.
What forms does PNC-27 come in?
PNC-27 is available in vial form.
How much does PNC-27 cost?
Prices start at $119.00 across 1 verified vendor.
How do I compare PNC-27 vendors?
Compare prices, payment methods, shipping, and COA scores across 1 vendor.
Research Tools
Related Compounds
View AllAminotadalafil
OtherPreclinicalAminotadalafil is an unapproved research analog of tadalafil, the PDE5 inhibitor marketed under the brand name Cialis for erectile dysfunction and under Adcirca for pulmonary arterial hypertension.
B7-33
OtherPreclinicalB7-33 is a single-chain, 26-amino-acid peptide engineered as a functionally selective agonist of the relaxin family peptide receptor 1 (RXFP1), designed to recapitulate the therapeutic activity of human H2 relaxin — the endogenous peptide hormone that is naturally elevated during pregnancy and has broad cardioprotective, vasodilatory, and anti-fibrotic effects.
KSPTN
OtherPreclinicalKSPTN is a novel research peptide available from select peptide research vendors.
Melanotan I
OtherFDA ApprovedMelanotan I (afamelanotide) is a linear synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) with the substitution of norleucine at position 4 and D-phenylalanine at position 7.
Prostamax
OtherPreclinicalProstamax is a short synthetic peptide developed in Russia by Vladimir Khavinson and collaborators at the St.
RU-58841
OtherPreclinicalRU-58841 (also known as PSK-3841 or HMR-3841, and commonly written simply as RU in hair-loss forums) is a non-steroidal androgen receptor antagonist originally developed by Roussel Uclaf (later absorbed into Sanofi) in the late 1980s and early 1990s.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
